Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38651558 | 0.81 | ALDH1A1 (0.38) | ALDH1A1POLBKMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL22325063 | 0.81 | GAA (0.38) | ALDH1A1POLBKMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL20855214 | 0.81 | ABL1 (0.38) | ALDH1A1POLBKMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL32684090 | 0.81 | CYP2C19 (0.33) | CYP2C19ABL1CD274KDM5BGAA | |
| SCHEMBL21663744 | 0.80 | RET (0.32) | ALDH1A1POLBCYP2C19LMNAABL1 | |
| SCHEMBL26108637 | 0.80 | CYP2C19 (0.32) | ALDH1A1POLBCYP2C19LMNAABL1 | |
| SCHEMBL22075031 | 0.78 | ABL1 (0.31) | CYP2C19LMNAABL1ESR1MAPT | |
| SCHEMBL16100426 | 0.78 | ALDH1A1 (0.34) | ALDH1A1POLBKMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL29339901 | 0.78 | KDM5B (0.33) | CYP2C19ABL1CD274KDM5BGAA | |
| SCHEMBL16099912 | 0.78 | ALDH1A1 (0.34) | ALDH1A1POLBKMT2ASMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132122-A1 | 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORS | INCYTE CORP (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2024182747-A2 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132122-A1 | 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORS | CCNA1, CDK4, CCNO | ALDH1A1 995/4885POLB 682/4885KMT2A 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.